DDInter485 DDInter1676
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Valrubicin
Daunorubicin {u} (Compound) treats {v} (Disease) hematologic cancer
Daunorubicin {u} (Compound) binds {v} (Gene) CYP1A2
Daunorubicin {u} (Compound) upregulates {v} (Gene) GDI1
Daunorubicin {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Daunorubicin {u} (Compound) downregulates {v} (Gene) TAF5
Daunorubicin {u} (Compound) causes {v} (Side Effect) Sickness
Daunorubicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Daunorubicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Daunorubicin (Compound) resembles Doxorubicin (Compound)
Daunorubicin (Compound) resembles Valrubicin (Compound)
Daunorubicin (Compound) treats hematologic cancer (Disease)
Daunorubicin (Compound) binds CYP1A2 (Gene)
Daunorubicin (Compound) upregulates GDI1 (Gene)
Daunorubicin (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class)
Daunorubicin (Compound) downregulates TAF5 (Gene)
Daunorubicin (Compound) causes Sickness (Side Effect)
Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Enoxacin